RXRX · Recursion Pharmaceuticals, Inc.
$2.96
-0.05 (-1.66%)
At close · Jul 24
Market Cap
$1.57B
Shares
529.91M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$74.68M
+26.9%
FY2025
Net Income
-$644.76M
-39.1%
FY2025
Gross Margin
4.99%
-18.1pp
FY2025
Operating Margin
-867.87%
-53.8pp
FY2025
Diluted EPS
-$1.44
+14.8%
FY2025
Operating Cash Flow
-$371.81M
-3.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $66.41M | $74.68M | $58.84M | $44.58M | $39.84M | $10.18M | $3.96M | $2.32M | |
| $61.61M | $70.95M | $45.24M | $42.59M | $48.28M | $0 | $0 | — | |
| $4.79M | $3.73M | $13.6M | $1.99M | -$8.43M | $10.18M | $3.96M | — | |
| — | 4.99% | 23.12% | 4.46% | -21.16% | 100% | 100% | — | |
| $433.53M | $475.27M | $314.42M | $241.23M | $155.7M | $135.27M | $63.32M | $45.81M | |
| $156.53M | $176.59M | $178.18M | $110.82M | $81.6M | $57.68M | $25.26M | $18.95M | |
| $51.3M | $50.3M | $18.8M | $8.5M | $379K | $304K | $126K | $0 | |
| — | $83.7M | $36.49M | $24.4M | $11.76M | $8.41M | $3.94M | $2.49M | |
| — | $9.84M | — | — | — | — | — | — | |
| — | — | — | — | — | $192.95M | $88.58M | $64.76M | |
| $651.68M | $722.81M | $537.84M | $394.64M | $285.57M | $192.95M | $88.58M | — | |
| -$585.27M | -$648.13M | -$479M | -$350.06M | -$245.73M | -$182.78M | -$84.62M | -$62.44M | |
| — | -867.87% | -814.09% | -785.33% | -616.74% | -1795.79% | -2135.66% | -2692.58% | |
| — | -$564.43M | -$442.51M | -$325.66M | -$233.97M | -$174.37M | -$80.67M | -$59.95M | |
| $1.65M | $1.81M | $1.57M | $97K | $55K | $2.95M | $1.36M | $635K | |
| $20.91M | $3.24M | $14.22M | $17.93M | $6.25M | -$3.7M | -$2.39M | $562K | |
| -$564.36M | -$644.9M | -$464.79M | -$332.13M | -$239.48M | -$186.48M | — | — | |
| -$4.58M | -$136K | -$1.13M | -$4.06M | $0 | $0 | $0 | $0 | |
| -$559.78M | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -$186.48M | -$87.01M | -$61.88M | |
| — | -863.35% | -788.02% | -735.99% | -601.05% | -1832.18% | -2196.01% | -2668.35% | |
| -$547.26M | -$600.41M | -$471.3M | -$328.07M | -$239.35M | -$186.61M | -$87.01M | -$61.88M | |
| USD/shares | — | -$1.44 | -$1.69 | -$1.58 | -$1.36 | -$1.49 | -$3.99 | -$2.87 |
| USD/shares | — | -$1.44 | -$1.69 | -$1.58 | -$1.36 | -$1.49 | -$3.99 | -$2.87 |
| shares | — | 447.45M | 274.21M | 207.85M | 175.54M | 125.35M | 21.78M | 21.57M |
| shares | — | 447.45M | 274.21M | 207.85M | 175.54M | 125.35M | 21.78M | 21.57M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $74,681,000 | $58,839,000 | $44,575,000 | $39,843,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $39,344,000 | $57,377,000 | $43,806,000 |
| United Kingdom | $35,337,000 | $1,135,000 | $0 |
| Other Countries | $0 | $327,000 | $769,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| License And Service | $74,256,000 | $58,488,000 | $43,876,000 | $39,681,000 | $10,000,000 | $3,413,000 | $1,711,000 |
| Grant | $425,000 | $351,000 | $699,000 | $162,000 | $178,000 | $549,000 | $608,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -$648,132,000 | -$479,004,000 | -$350,060,000 | -$245,727,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -867.9% | -814.1% | -785.3% | -616.7% |
Key facts
CIK
1601830
CUSIP
75629V104
13F (30d)
60 filings
60 filers
Visit website
Investor relations